AVZO-023
PreclinicalSmall molecule
AVZO-023 is one of 12 small molecule programs targeting HR+/HER2- Breast Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in HR+/HER2- Breast Cancer
#DrugCompanyPhaseTrials
1Femara
NovartisPhase 3
Halaven
EisaiPhase 3
Gemzar
Johnson & JohnsonPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Ellence
PfizerPhase 2
BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Serplulimab
Shanghai Henlius BiotechPhase 2
Albumin Paclitaxel
CChipscreen Biosciences, Ltd.
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AVZO-023. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAvenzo Therapeutics, Inc.